Aim of the study was to investigate the predictive value of circulating vascular endothelial growth factor-1 level for recurrent cardiovascular events in hypertensive patients after acute ischemic stroke.
Introduction
Numerous factors involved in the adaptive response to ischemic stroke, including vascular endothelial growth factor are transcriptionally regulated by hypoxia-inducible factors [1] and is produced pronounced angiopoetic capacity [2] . VEGF-1 realizes their biological effect thereby cooperation with tyrosine kinase receptors located on endothelial cells surface that leads to cells growth, proliferation, and migration, as well as neovascularization and angiogenesis [3] . However, the predictive role of VEGF-1 as a marker of endothelial dysfunction in patients after acute ischemic stroke is still not clear. The aim of the study was to investigate the predictive value of circulating vascular endothelial growth factor-1 level for recurrent cardiovascular events in hypertensive patients after acute ischemic stroke.
Methods
It has been enrolled 102 post-discharged patients with arterial hypertension after acute ischemic stroke. Neurological impairment at presentation was assessed by National Institute of Health Stroke Scale (NIHSS) (National Institute of Health Stroke Scale) [4] . The Barthel Index [5] and the modified Rankin Scale [6] were used to assess functional disability. Contrast-enhanced computer spiral tomography (CT) was performed on a "Somatom Spirit" scanner (Siemens, Germany) with 2 rows of detectors. Nonionic contrast "Omnipak" (Amersham Health, Ireland) was used. All samples were collected in cooling vacutaner and after that it was immediately centrifuged (4°C for 6.000 × 15 min). After centrifugation serum was blind coded and stored at -70° until used. Concentrations of VEGF-1 were measured by ELISA at baseline and in 6 months of observation using laboratory kits produced by Bioscience (USA). All determinations were done by duplicate. Concentrations of total and HDL cholesterol were determined by a Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). LDL cholesterol was calculated by using the formula of Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) . Clinical interviews were performed every month during 1 year period after baseline. Clinical events included following: new cases of stroke or TIA; death for any reasons and sudden cardiac death; coronary ischemic events (myocardial infarction, unstable angina, arrhythmia), needing of hospitalization for cardiovascular reasons, newly onset chronic heart failure and diabetes mellitus. Newly diagnostic stroke incidences were obligatory rule in CT. The diagnosis of heart failure was defined as an unplanned hospital admission for which the primary reason was clinical heart failure and it was based on clinical symptoms (limitation of activity, fatigue, and dyspnoea), physical signs (oedema, elevated jugular venous pressure, rales, or third heart sound with gallop), LVEF lowering obtained by Echo-examination, or radiological evidence of pulmonary congestion, and requirement of high dose loop diuretic, intravenous nitrate using or inotropic support. All clinical events were presented as cumulative.
Statistical Analysis
All statistical analyses were performed in SPSS for Windows v. 17.0 (SPSS Inc., Chicago, Il, USA). All values were given as mean and 95% CI or median and percentiles. An independent group t-test was used for comparisons for all interval parameters meeting the criteria of normality and homogeneity of variance. For interval parameters not meeting these criteria, the non-paramentric Mann-Whitney test was used to make comparisons between groups. Comparisons of categorical variables between groups were performed using the Chi2 test, and the Fisher exact test. Receiver operating characteristic (ROC) curves were configured to establish cutoff points of VEGF-1 levels that optimally predicted the occurrence of cumulative clinical events. Kaplan-Meier survival curves were estimated for hypertensive patients depend on VEGF-1 levels. A calculated difference of P<0.05 was considered significant.
Results
One hundred two post-discharged patients (67 men and 35 women; mean age, 58.38 years [95% CI = 54-72 years]) with mild-to-moderate arterial hypertension were included in this study in 3 weeks after first clinical signs of ischemic stroke.
Baseline characteristics of the study group are presented in Table 1 . All included patients were hypertensive at the screening (78 subjects with mild hypertension, and 24 subjects with moderated hypertension). All patients were included in the study after achieved goal blood pressure (less than 140 / 90 mm Hg). Besides 45.1% enrolled subjects had dyslipidemia, 42.2% patients were smoked, and 14.7% patients had a history of mild diabetes mellitus. We found right-side injury of brain in 63.7% cases; in 34.3% and 2% left-side and two-side injuries were defined. NIHSS score was 10 (interquartile range of 7-18), the median Barthel Index score was 65 (interquartile range of 40 to 85); and the median Rankin Scale score was 4 (interquartile range of 2 to 5). No significant differences between cohorts regarding age, sex, BP at the study entry, cardiovascular risk factors (BMI, dyslipidemia, low-density cholesterol, fasting glucose), initial NIHSS score, initial Barthel Index score, initial Rankin Scale score. T2DM was occurred a much higher in cohort with clinical events when compared with free clinical events patients. Total cholesterol plasma level was a significant higher in cohort patients with clinical event occurred in comparison to free-event patients. Median of total cholesterol and low-density cholesterol (LDL-C) plasma levels were 5.28 mmol/L (95% CI =3.82-6.74) and 3.26 mmol/L (95% CI =2.14-4.38) respectively. Treatment strategy was similar in both cohorts, but there was a significant increased frequency of agntiaggregants distinguished form aspirin in patients with clinical events occurred. Statins before admission were prescribed much often in free-events cohort patients. It has taken into consideration that at the study entry proportions of the patients with statins prescribing was similar. Target levels of LDL-C less 1.8 mmol/L and less 2.5 mmol/L were achieved in 23 (22.5%) and 33 (32.4%) patients at the study entry. Statins (atorvastatin in 56 cases, and simvastatin in 15 cases) before admission were taken 71 (69.6%) enrolled subjects. After admission there was not withdrawing of statins at all, and at the study entry 82 (80.4%) patients have been taking atorvastatin in median daily orally dosage equivalent of 40 mg (interquartile range of 20 mg to 80 mg). All subjects before study entry were hemodynamically stable and they have controlled arterial hypertension and remained free of any ischemic events during the time elapsed between the first qualifying episode and the inclusion visit date. During observation period 57 cumulative clinical events occurred and they were identified in 48 patients (47.1%). They were distributed in 4 deaths, 6 cardiac arrhythmias, 17 cardiac ischemic events, 9 stroke (5 lacunar infarctions, and 2 cardioembolic strokes), 10 diabetes mellitus, 4 chronic heart failure and 7 hospitalizations for cardiovascular reasons, including newly chronic heart failure. Note: T2DM -type two diabetes mellitus, NIHSS -National Institute of Health Stroke Scale, BMI -body mass index, LDL -low density lipoprotein, * -significance differences between cohorts (P<0.05).
Analysis of obtained results has been shown that median of peak VEGF-1 concentration in subjects with recurrent cardiovascular events when compared with patients without it were similar (Me=344.87 pg / ml, 95% CI=245.67-493.46 pg / ml and Me=352.10 pg / ml, 95% CI=205.31-573.81 pg / ml respectively, P>0.1). The significant difference between VEGF-1 concentrations in hypertensive patients depended on age, gender, types of ischemic stroke, severity of hypertension, and blood pressure values at baseline as well as in depended on conventional cardiovascular risk factors, NIHSS, Barthel index, and Rankin score index was found. For further analysis concentration of VEGF-1 was presented depended on numerous of recurrent cardiovascular events in follow-up. We found that circulating VEGF-1 levels in patients with one, two, three and more recurrent cardiovascular events were 373.80 pg/ml (95% CI=342.90-479.70 pg/ml), 539.96 pg/ml (95% CI=444.28-865.56 pg/ml) and 724.66 pg/ml (95% CI=558.72-890.66 pg/ml) respectively. Moreover, VEGF-1 levels for these subjects were significantly higher than patients of free events (Ме=289.28 pg/ml; 95% CI=279.71-345.88 pg/ml) (P=0.001). Using ROC-analysis, we found that the most optimal cutoff-point of circulating VEGF-1 in hypertensive patients at baseline was 403.57 pg / ml (sensitivity and specificity were 78.6% and 70.0%). Area under ROC curve (AUC) was 0.76 (95% CI=0.602-0.917; P=0.001).
Kaplan-Meier curves revealed ( Figure 1 ) an accumulation of cardiovascular events was superior in patients with peak VEGF-1 level more 403.57 pg / ml when compared with subjects with VEGF-1 level less this cutoff point (P=0.001). Thus, these data allowed us to establish the fact that circulating peak VEGF-1 closely associates with increased risk of recurrent cardiovascular events in patients with controlled hypertension. 
P<0.001

Discussion
Results of the study demonstrate that peak VEGF-1 level was an independent one-year predictor of cardiovascular outcomes in hypertensive patients after acute ischemic stroke. It has predisposed that peak concentrations of VEGF-1 among symptomatic atherosclerotic carotid plaque patients may have a predicted value [7] . Although neuroprotective capacities for VEGF-1 were found [8, 9] , VEGF-1 is able to induce post-ischemic neurovascular remodeling and apoptosis [10] . Probably, these mechanisms underlie the violation of spatial progressive perivascular citoarchitectonics, expanding penumbra zone and worsening cerebral ischemia [11] . It has suggested that immediate effects of VEGF-1 in hypertensive patients after acute ischemic stroke probably are adaptive, while deferred effects may be associated with recurrent clinical events, in particular, mediated by atherothrombosis [12, 13] . This hypothesis was confirmed by the results of our study. It should be noted that all patients included in the trial had controlled blood pressure, and the majority of them continued to receive ACE inhibitors, calcium channel blockers, statins and antiplatelet therapy after stroke. Taken into consideration a small size of the study new investigations with greater statistical power are required.
In conclusion, we found that increase of peak VEGF-1 level in hypertensive patients after ischemic stroke had one-year predicted value for cardiovascular recurrent events.
Limitations of the study
This study has some limitations. We believed that a greater cohort would be desirable to improve the power of the study because low rates of recurrent strokes and deaths were detected. We also relied on clinical data to rule out infection and other inflammatory diseases before sampling, but we cannot exclude that some patients had unrecognized conditions responsible for the elevated VEGF-1 levels observed. However, additional verification of atherosclerosis as well as intracranial artery occlusive disease can be required. We supposed that these limitations might not have a significant influence to study data interpretation.
